Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $485,771.97 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 2,103 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $485,771.97. Following the completion of the sale, the chief marketing officer now owns 15,609 shares in the company, valued at approximately $3,605,522.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alnylam Pharmaceuticals Stock Down 1.6 %

ALNY stock opened at $243.00 on Friday. The business has a fifty day moving average of $159.86 and a two-hundred day moving average of $164.73. The stock has a market cap of $30.74 billion, a price-to-earnings ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. Alnylam Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. During the same period last year, the business earned ($1.40) EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 51 shares during the period. EP Wealth Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 71 shares during the period. Commerce Bank boosted its position in shares of Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after buying an additional 77 shares during the period. Envestnet Portfolio Solutions Inc. boosted its position in shares of Alnylam Pharmaceuticals by 7.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 89 shares during the period. Finally, Metis Global Partners LLC boosted its position in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after buying an additional 94 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ALNY shares. SVB Leerink increased their price target on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday. TD Cowen increased their price target on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research report on Tuesday. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Chardan Capital restated a “buy” rating and issued a $225.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Eight research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $247.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.